Intensity Therapeutics, Inc. (INTS)
INTS Stock Price Chart
Explore Intensity Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze INTS price movements and trends.
INTS Company Profile
Discover essential business fundamentals and corporate details for Intensity Therapeutics, Inc. (INTS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Jun 2023
Employees
5.00
CEO
Lewis H. Bender
Description
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
INTS Financial Timeline
Browse a chronological timeline of Intensity Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.87.
Earnings released on 7 May 2026
EPS came in at -$0.96 surpassing the estimated -$1.19 by +19.33%.
Earnings released on 27 Mar 2026
EPS came in at -$1.69 falling short of the estimated -$1.24 by -36.29%.
Stock split effective on 19 Feb 2026
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 6 Nov 2025
EPS came in at -$0.06 matching the estimated -$0.06.
Earnings released on 7 Aug 2025
EPS came in at -$0.13 falling short of the estimated -$0.06 by -116.67%.
Earnings released on 13 May 2025
EPS came in at -$0.22 falling short of the estimated -$0.21 by -4.76%.
Earnings released on 13 Mar 2025
EPS came in at -$0.22 surpassing the estimated -$0.23 by +4.35%.
Earnings released on 13 Nov 2024
EPS came in at -$0.25 surpassing the estimated -$0.27 by +7.41%.
Earnings released on 8 Aug 2024
EPS came in at -$0.36 falling short of the estimated -$0.32 by -12.50%.
Earnings released on 9 May 2024
EPS came in at -$0.34 .
Earnings released on 14 Mar 2024
EPS came in at -$0.12 surpassing the estimated -$0.18 by +33.33%.
Earnings released on 13 Nov 2023
EPS came in at -$0.17 falling short of the estimated -$0.09 by -88.89%.
Earnings released on 14 Aug 2023
EPS came in at -$1.43 falling short of the estimated -$0.40 by -257.50%.
Earnings released on 30 Jun 2023
EPS came in at -$63.77 .
Earnings released on 31 Dec 2022
EPS came in at -$72.06 .
Earnings released on 30 Sept 2022
EPS came in at -$71.36 .
Earnings released on 30 Jun 2022
EPS came in at -$66.96 .
Earnings released on 31 Mar 2022
EPS came in at -$113.03 .
Earnings released on 31 Dec 2021
EPS came in at -$83.41 .
Earnings released on 30 Sept 2021
EPS came in at -$73.80 .
INTS Stock Performance
Access detailed INTS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
